Establishment	O
and	O
application	O
of	O
a	O
flow	B:C0016263
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
Histone	O
deacetylase	I:C1512474
inhibitors	I:C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	I:C0003392
developed	O
in	O
recent	O
years	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	B:C0025663
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
Histone	O
deacetylase	I:C1512474
inhibitors	I:C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	I:C0003392
developed	O
in	O
recent	O
years	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	B:C0442726
histone	O
acetylation	I:C1156200
levels	O
Histone	O
deacetylase	I:C1512474
inhibitors	I:C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	I:C0003392
developed	O
in	O
recent	O
years	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	B:C1156200
acetylation	I:C1156200
levels	O
Histone	O
deacetylase	I:C1512474
inhibitors	I:C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	I:C0003392
developed	O
in	O
recent	O
years	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	I:C0003392
developed	O
in	O
recent	O
years	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
Histone	O
deacetylase	I:C1512474
inhibitors	I:C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	B:C0001175
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	I:C0003392
developed	O
in	O
recent	O
years	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
Histone	O
deacetylase	I:C1512474
inhibitors	I:C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	B:C0012634
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	I:C0003392
developed	O
in	O
recent	O
years	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
Histone	O
deacetylase	I:C1512474
inhibitors	I:C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	B:C0003392
drugs	I:C0003392
developed	O
in	O
recent	O
years	O
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	B:C0025663
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	O
for	O
detecting	B:C0442726
histone	O
acetylation	I:C1156200
levels	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	O
for	O
detecting	O
histone	B:C1156200
acetylation	I:C1156200
levels	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
in	O
basic	B:C0681833
and	O
clinical	O
research	I:C0008972
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
in	O
basic	O
and	O
clinical	B:C0008972
research	I:C0008972
.	O

In	O
this	O
study	B:C2603343
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	B:C0016263
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	B:C0025663
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	B:C1511790
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	B:C1156200
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	B:C0020746
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	B:C1822393
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	B:C0007605
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	B:C0025663
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	B:C0021868
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	B:C0028584
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	B:C0003241
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	B:C0522986
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	B:C0003241
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	B:C0370231
blood	I:C0370231
and	O
peripheral	O
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
to	O
detect	O
histone	O
acetylation	I:C1156200
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	I:C1822393
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	O
titration	I:C0522986
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	I:C0370231
and	O
peripheral	B:C1321301
blood	I:C1321301
mononuclear	I:C1321301
cells	I:C1321301
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	B:C0025663
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	B:C0681814
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	B:C0008976
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	B:C2932486
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	B:C0008115
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	B:C2700205
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	B:C0750484
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	B:C0016263
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	B:C0025663
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	B:C0442726
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	B:C1156200
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	B:C0025663
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	B:C0681833
and	O
clinical	O
research	I:C0008972
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	I:C0008976
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	I:C2700205
HDACi	I:C2700205
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	I:C0016263
-	O
based	O
method	O
for	O
detecting	O
histone	O
acetylation	I:C1156200
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	B:C0008972
research	I:C0008972
.	O

